Results of a phase III clinical trial has indicated that the drug enzalutamide can extend survival by an average of five months in patients afflicted with advanced stages of prostate cancer. Despite warnings that this drug should not be administered to patients with history of seizure, stroke, alcoholism, brain injury, or brain metastases, "enzalutamide reduced the risk of death from any cause by 37% versus placebo.
More information on the trial can be found here.
Study mentioned: Scher HI et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Aug 15 [Epub ahead of print]. PMID 22894553
No comments:
Post a Comment